NEUROONE MEDICAL TECHNOLOGIES Corp·4

Apr 1, 4:01 PM ET

Rosa David A 4

4 · NEUROONE MEDICAL TECHNOLOGIES Corp · Filed Apr 1, 2026

Research Summary

AI-generated summary of this filing

Updated

NeuroOne (NMTC) CEO David A. Rosa Surrenders 2,458 Shares for Taxes

What Happened

  • David A. Rosa, CEO, President and Director of NeuroOne Medical Technologies Corp (NMTC), disposed of 2,458 shares on 2026-03-31. The filing reports the shares were surrendered at $0.78 per share for a total of $1,910 to satisfy a tax withholding or exercise payment obligation (transaction code F). This is a withholding/tax-related disposition rather than an open-market sale.

Key Details

  • Transaction date: 2026-03-31; Filing date (Form 4): 2026-04-01 (timely).
  • Shares disposed: 2,458 at $0.78 per share; total value reported: $1,910.
  • Transaction code: F — payment of exercise price or tax liability (typically shares surrendered to cover withholding).
  • Shares owned after the transaction: not specified in the summary data of the filing.
  • This is not reported as a market sale (code S) and appears routine for tax withholding after an equity event.

Context

  • For retail investors: disposals under code F usually reflect tax withholding after an option exercise or vesting and do not necessarily signal a change in the insider’s view of the company. The cash value involved here is small (~$1.9K) relative to typical insider trades.

Insider Transaction Report

Form 4
Period: 2026-03-31
Rosa David A
DirectorCEO and President
Transactions
  • Tax Payment

    Common Stock

    2026-03-31$0.78/sh2,458$1,9101,080,132 total
Signature
/s/ Emily Johns, by Power of Attorney|2026-04-01

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT